These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25490004)

  • 1. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Lara PN; Moon J; Redman MW; Semrad TJ; Kelly K; Allen JW; Gitlitz BJ; Mack PC; Gandara DR
    J Thorac Oncol; 2015 Jan; 10(1):110-5. PubMed ID: 25490004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.
    Allen JW; Moon J; Redman M; Gadgeel SM; Kelly K; Mack PC; Saba HM; Mohamed MK; Jahanzeb M; Gandara DR
    J Clin Oncol; 2014 Aug; 32(23):2463-70. PubMed ID: 25002722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
    Gitlitz BJ; Moon J; Glisson BS; Reimers HJ; Bury MJ; Floyd JD; Schulz TK; Sundaram PK; Ho C; Gandara DR
    J Thorac Oncol; 2010 Nov; 5(11):1835-40. PubMed ID: 20881645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.
    Lara PN; Moon J; Redman MW; Semrad TJ; Kelly K; Allen J; Gitlitz B; Mack PC; Gandara DR
    Clin Lung Cancer; 2016 Mar; 17(2):113-8.e1-2. PubMed ID: 26498504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy.
    Qi W; Zhao S; Chen J
    Cancer Biomark; 2021; 31(2):177-185. PubMed ID: 33896825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
    Song Z; Shao L; Lin B; Zhang Y
    Clin Transl Oncol; 2013 Oct; 15(10):843-8. PubMed ID: 23423808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
    Lara PN; Chansky K; Davies AM; Franklin WA; Gumerlock PH; Guaglianone PP; Atkins JN; Farneth N; Mack PC; Crowley JJ; Gandara DR
    J Thorac Oncol; 2006 Nov; 1(9):996-1001. PubMed ID: 17409985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute].
    Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
    Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):8-14. PubMed ID: 24398308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
    Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
    JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.
    Ardizzoni A; Tiseo M; Boni L
    Eur J Cancer; 2014 Sep; 50(13):2211-8. PubMed ID: 24981975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy versus best supportive care for extensive small cell lung cancer.
    Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
    Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD001990. PubMed ID: 24282143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
    Heist RS; Fain J; Chinnasami B; Khan W; Molina JR; Sequist LV; Temel JS; Fidias P; Brainerd V; Leopold L; Lynch TJ
    J Thorac Oncol; 2010 Oct; 5(10):1637-43. PubMed ID: 20808253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
    Takahashi N; Hao Z; Villaruz LC; Zhang J; Ruiz J; Petty WJ; Mamdani H; Riess JW; Nieva J; Pachecho JM; Fuld AD; Shum E; Chauhan A; Nichols S; Shimellis H; McGlone J; Sciuto L; Pinkiert D; Graham C; Shelat M; Kattappuram R; Abel M; Schroeder B; Upadhyay D; Krishnamurthy M; Sharma AK; Kumar R; Malin J; Schultz CW; Goyal S; Redon CE; Pommier Y; Aladjem MI; Gore SD; Steinberg SM; Vilimas R; Desai P; Thomas A
    JAMA Oncol; 2023 Dec; 9(12):1669-1677. PubMed ID: 37824137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer.
    Miura Y; Imai H; Sakurai R; Kaira K; Sunaga N; Minato K; Saito R; Hisada T
    Med Oncol; 2018 Mar; 35(4):45. PubMed ID: 29508094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
    Dingemans AM; Mellema WW; Groen HJ; van Wijk A; Burgers SA; Kunst PW; Thunnissen E; Heideman DA; Smit EF
    Clin Cancer Res; 2013 Feb; 19(3):743-51. PubMed ID: 23224737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.
    Paz-Ares L; Hirsh V; Zhang L; de Marinis F; Yang JC; Wakelee HA; Seto T; Wu YL; Novello S; Juhász E; Arén O; Sun Y; Schmelter T; Ong TJ; Peña C; Smit EF; Mok TS
    J Thorac Oncol; 2015 Dec; 10(12):1745-53. PubMed ID: 26743856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.